Lilly extends study of highly anticipated cholesterol fighter

Eli Lilly's ($LLY) drug candidate evacetrapib, a CETP inhibitor that works to lower LDL, or "bad," cholesterol levels and raise HDL, or "good," cholesterol levels, is highly anticipated. But the drugmaker says it will extend the massive Phase III trial for the cardio treatment by 6 months. It says the reason is because of some new science, but the move is sure to raise concerns about the drug's potential, FierceBiotech points out. Lilly says that is not at all the reason. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.